$18.5 million to help eight innovative startups commercialise their research into medicinal treatments
03 Jan 2025
This investment through the MRFF’s Medical Research Commercialisation initiative will lead to new medicines and treatment tools including:
- gene therapy that regenerates cells in the eye to help restore vision
- a device that helps surgeons find cancer cells during surgery
- software that can identify pregnant women likely to experience severe bleeding during childbirth
- a drug that helps doctors to find out earlier if cancer treatment has been successful
- improved CAR T-cell therapy for the treatment of solid tumour cancers like breast, colon, pancreas and prostate cancers
- a drug that reduces agitation and aggression in people with dementia
- a safer and more effective drug to treat inflammatory bowel disease
- software that reduces the side effects of breast cancer treatment by making radiation therapy target cancerous cells only.
The startups are the first group to receive funding through the CUREator+ program. Brandon BioCatalyst delivers CUREator+ in partnership with ANDHealth.
Read the media release for more information.
Learn about the MRFF.
